Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Irritable Bowel Drugs From Salix, Actavis Await FDA Action In 2015

This article was originally published in The Pink Sheet Daily

Executive Summary

With new retreatment data in hand, Salix is again pursuing a supplemental claim for the antibacterial Xifaxan, while Actavis is seeking approval of eluxadoline, a new molecular entity with dual opioid receptor activity.


Related Content

Actavis Flexes Its Commercial Muscles Ahead Of Allergan Integration
Valeant Reasons, Ackman Threatens In Latest Allergan Takeover Moves
Valeant Reasons, Ackman Threatens In Latest Allergan Takeover Moves
Synthetic Biologics Thinks Statins May Get At Root Of IBS-Constipation
Furiex Makes Inroads In Tough-To-Treat IBS-d With Positive Phase III Eluxadoline Data
IBS Trials Should Gauge Efficacy In Maintenance And Retreatment, FDA Says
Data On Length Of Symptom Relief Could Improve Xifaxan Trial, Panel Members Suggest
Panel To Help Define Target Population For Xifaxan Reuse In IBS-D
IBS-D Lead May Go To Tioga With Salix Required To Run Another Trial
Salix Tumbles With Expected "Complete Response" Letter On Xifaxan In IBS


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts